Clinical trial number NCT02055638 for "Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder (AVN009)" at ClinicalTrials.gov
doi.org
Fabio KM, Guillon CD, Lu SF, Heindel ND, Brownstein MJ, Lacey CJ, et al. (June 2013). "Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist". Journal of Pharmaceutical Sciences. 102 (6): 2033–2043. doi:10.1002/jps.23495. PMID23471831.
Simon NG, Guillon C, Fabio K, Heindel ND, Lu SF, Miller M, et al. (June 2008). "Vasopressin antagonists as anxiolytics and antidepressants: recent developments". Recent Patents on CNS Drug Discovery. 3 (2): 77–93. doi:10.2174/157488908784534586. PMID18537767.
Fabio KM, Guillon CD, Lu SF, Heindel ND, Brownstein MJ, Lacey CJ, et al. (June 2013). "Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist". Journal of Pharmaceutical Sciences. 102 (6): 2033–2043. doi:10.1002/jps.23495. PMID23471831.
Simon NG, Guillon C, Fabio K, Heindel ND, Lu SF, Miller M, et al. (June 2008). "Vasopressin antagonists as anxiolytics and antidepressants: recent developments". Recent Patents on CNS Drug Discovery. 3 (2): 77–93. doi:10.2174/157488908784534586. PMID18537767.